Resultados de procura - Simone Claudiani

Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations por Simone Claudiani, Jane F. Apperley, Afzal Khan, Jamshid Khorashad, Dragana Milojkovic

Ligazón do recurso

Changes in Common Blood Parameters After Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukaemia por Fiona Fernando, Claudia Wasko, Bronwen Johns, Simone Claudiani, Afzal Khan, Andrew J. Innes, Dragana Milojkovic, Jane F. Apperley

Ligazón do recurso

Thrombocytosis and bleeding in myeloproliferative neoplasms: exploring clinical diversity and risk of acquired von Willebrand syndrome—insights from a UK center por Giulia Simini, Andrew Innes, Saravanan Vinayagam, Golzar Mobayen, Nilanthi Karawitage, Simone Claudiani, Zain Odho, Mike Laffan, Deepa J. Arachchillage

Ligazón do recurso

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy por Simone Claudiani, Jane F. Apperley, Robert Peter Gale, Richard Clark, Richard Szydlo, Simona Deplano, Renuka Palanicawandar, Jamshid Khorashad, Letizia Foroni, Dragana Milojkovic

Ligazón do recurso

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia por Simone Claudiani, Aoife Gatenby, Richard Szydlo, George Nesr, Adi Shacham Abulafia, Renuka Palanicawandar, Georgios Nteliopoulos, Jamshid Khorashad, Letizia Foroni, Jane F. Apperley, Dragana Milojkovic

Ligazón do recurso

FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions por Philippa C. May, Alistair G. Reid, Mark E. Robinson, Jamshid S. Khorashad, Dragana Milojkovic, Simone Claudiani, Genomics England Research Consortium, Fenella Willis, Jane F. Apperley, Andrew J. Innes

Ligazón do recurso

Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score por Fiona Fernando, Maria Sol Andres, Simone Claudiani, Nazanin Zounemat Kermani, Giulia Ceccarelli, Andrew J. Innes, Afzal Khan, Stuart D. Rosen, Jane F. Apperley, Alexander R. Lyon, Dragana Milojkovic

Ligazón do recurso

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors por Georgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, Gareth Gerrard, Edward Curry, Richard Szydlo, Mary Alikian, Hui En Foong, Zacharoula Nikolakopoulou, Sandra Loaiza, Jamshid S. Khorashad, Dragana Milojkovic, Danilo Perrotti, Robert Peter Gale, Letizia Foroni, Jane F. Apperley

Ligazón do recurso